Baird lowered the firm’s price target on Sarepta (SRPT) to $60 from $193 and keeps an Outperform rating on the shares. The firm updated its model following disappointing Q1 results amid regualtory uncertainty which amplifies its risks.
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $98 from $112 at Guggenheim
- Long-Term Potential and Strategic Developments Drive Buy Rating for Sarepta Therapeutics Despite Short-Term Challenges
- Sarepta price target lowered to $70 from $110 at Piper Sandler
- Sarepta Therapeutics: Buy Rating Affirmed Amid Revenue Challenges and Strategic Adjustments
- Sarepta Therapeutics: Buy Rating Affirmed Amidst Strong Growth and Strategic Resilience